Information 206, Piazza San Carlo Torino Italy Ciro Spedaliere, Pietro Puglisi +39 / 011 3325889 info@clarisventures.com http://www.clarisventures.com Structure Number of executives:3 Number of funds managed/advised:2 Number of funds art. 8 sfdr 1:1 Number of funds art. 9 sfdr n.a.:N.A. Total capital under management/advised:€170.000.000 Number of portfolio companies:11 Investment policy Minimum investment:1.000.000 € Maximum investment:5.000.000 € Geographical preferences: Investment focus: Sectoral preferences: Remarks Claris Ventures is a venture capital operator based in Italy specialized in early stage investments in companies active in the development of new drugs with high potential, born from the Italian research network – both local and international. The objective of Claris Ventures is to identify and support innovations in the pharmaceutical field, investing in new companies that develop potential drugs that can revolutionize the current treatment scenario in indications with limited therapeutic alternatives. The investment strategy is focused on biotech projects ready to start clinical studies in which Claris Ventures will provide the resources to fund the eventual completion of preclinical studies and a first human study. Informazioni 206, Piazza San CarloTorinoItaly Ciro Spedaliere, Pietro Puglisi +39 / 011 3325889 info@clarisventures.com http://www.clarisventures.com Remarks Claris Ventures is a venture capital operator based in Italy specialized in early stage investments in companies active in the development of new drugs with high potential, born from the Italian research network – both local and international. The objective of Claris Ventures is to identify and support innovations in the pharmaceutical field, investing in new companies that develop potential drugs that can revolutionize the current treatment scenario in indications with limited therapeutic alternatives. The investment strategy is focused on biotech projects ready to start clinical studies in which Claris Ventures will provide the resources to fund the eventual completion of preclinical studies and a first human study.